HWHatus V. Wanderley

Hatus V. Wanderley

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hatus V. Wanderley has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Angela R. Shih

    Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA

    1 shared publication
  • Bijan Safaee Fakhr

    Mass General Brigham, Harvard Medical School, Boston, Massachusetts

    1 shared publication
  • Binglan Yu

    Anesthesia Center for Critical Care Research, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA

    1 shared publication
  • Carolyn J. LaVita

    Dr. Ribeiro De Santis Santiago and Ms. LaVita are affiliated with the Respiratory Care Department, Massachusetts General Hospital, Boston, Massachusetts

    1 shared publication
  • Cristina Mietto

    Anesthesia Center for Critical Care Research, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

    1 shared publication
  • Dario Winterton

    Anesthesia Center for Critical Care Research, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

    1 shared publication

Latest Publications

  • Inhaled nitric oxide at 300 ppm treats multidrug-resistant Pseudomonas pneumonia in swine and is safe in humans

    by Binglan Yu, Bijan Safaee Fakhr, Lynn Bry, Angela Shih, Hatus V. Wanderley, Yue Dai, Ryan W. Carroll, Dario Winterton, Talisa Buehl, Mohamed Okda, et al.

    Antibiotic resistance in respiratory infections is an escalating global concern that requires innovative antimicrobial approaches. Pseudomonas aeruginosa is a common multidrug-resistant pathogen and a major cause of hospital-acquired pneumonia. Accumulating evidence suggests that, at high doses, inhaled nitric oxide (iNO) acts as a potent antimicrobial agent. This study evaluated the efficacy and safety of iNO at 300 parts per million (iNO 300 ) as a treatment for P. aeruginosa infection. In vitro, P. aeruginosa exhibited a dose-dependent reduction when exposed to an NO donor. In a mechanically ventilated swine model of P. aeruginosa pneumonia, intermittent iNO 300 therapy resulted in a two-log reduction in bacterial burden, improved oxygenation and lung compliance, and reduced histopathological lung injury. A phase 1 clinical trial in 10 healthy individuals confirmed the safety of intermittent iNO 300 therapy with no adverse events. In two critically ill patients with multidrug-resistant bacteria, who were in the intensive care unit, iNO 300 was well tolerated, demonstrating clinical feasibility. Long-term follow-up of patients exposed to high-dose iNO for more than 6 years revealed no adverse outcomes. Our findings establish iNO 300 as a promising antimicrobial agent against P. aeruginosa pneumonia, warranting further clinical evaluation.